In the present study, CSF concentrations of NFL, t-tau, p-tau, GFAP, S-100B, YKL-40, MCP-1, α-sAPP, β-sAPP, and Aβ38, Aβ40, Aβ42 were measured in 324 MS patients to test whether a correlation among the biomarkers exists and whether the profile of CSF biomarkers varies among the different types of MS. The CSF concentrations of NFL were significantly higher in RRMS while CSF concentrations of GFAP were higher in PPMS. CSF concentrations of NFL correlated with YKL-40 in CIS patients while CSF concentrations of GFAP correlated with YKL-40 in RRMS patients.
Introduction
Multiple sclerosis (MS) is classically described as a demyelinating disease of the central nervous system (CNS) due to the histological findings of white matter lesions in brains. However, there is evidence that not only myelin and oligodendrocytes are implied in MS pathogenesis, but also neuronal damage and astroglial activation (Eng and Ghirnikar,1994; Bonneh-Barkay et al., 2010; Trapp et al., 1998; Filippi et al., 2003) . Clinically, MS is considered a chronic autoimmune condition. Even though, the involvement of the immune system has been thoroughly described in MS, there is also evidence that diffuse neurodegenerative processes takes part in the MS pathogenesis from the early stages of the disease (Frischer et al., 2009) . Probably, the predominance of autoimmune activation at the onset of the disease explains the inflammatory course of the relapsing-remitting forms of MS. While the predominance of neuronal and glial degeneration would be associated with progressive forms of MS. Ideally, knowing the underlying histopathological process in each MS patient could lead to an individual treatment for a specific target. Notwithstanding, it is not feasible to obtain brain biopsies. Thus, MS patients are classified by their clinical course as clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS), and they are treated according to the international standards.
Cerebrospinal fluid (CSF) is the closest body fluid to brain tissue (Blennow et al., 2010) . Therefore, CSF from a diagnostic lumbar puncture could reflect the features of brain damage at MS onset and could differentiate the different patterns of MS.
The purpose of the present study was to investigate glial and neuronal biomarkers in CSF samples from patients with different types of MS and to test whether a correlation among the biomarkers exists and whether the profile of CSF biomarkers varies among the different types of MS. Hence, we analysed biomarkers related to axonal damage (neurofilament light protein: NFL) (Trapp et al., 1998) , neuronal injury (total-tau: t-tau and tau phosphorylated at threonine 181: p-tau) (Binder et al., 1985) , glial activation (human chitinase 3-like 1 protein: YKL-40 and monocyte chemoattractant protein: MCP-1) (Bonneh-Barkay et al., 2010; Van Der Voorn et al., 1999) , astrocytic damage (glial fibrillary acidic protein: GFAP and S-100B protein: S-100B) (Eng and Ghirnikar, 1994; Donato, 2001) , and amyloid metabolism (α-cleaved soluble amyloid-precursor protein: α-sAPP; β-cleaved soluble amyloid-precursor protein: β-sAPP; 38,
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